# A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

> **NCT04857034** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 74 (actual)

## Conditions studied

- Lupus Erythematosus, Discoid
- Lupus Erythematosus, Subacute Cutaneous

## Interventions

- **DRUG:** Deucravacitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04857034
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-12
- **Primary completion:** 2024-08-22
- **Final completion:** 2028-02-28
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04857034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04857034, "A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04857034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*